http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0147283-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-868 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-866 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
filingDate | 1984-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 1989-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 1989-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0147283-B1 |
titleOfInvention | Immunomodulating medicine based on fc fragments of human igg |
abstract | This medication consists of Fc fragments of human IgG, or of analogues of said fragments, and [is characterized by the fact] that it is free of intact IgG and/or Fab fragments or contains no more than 2% by weight of the latter with respect to total weight (Fc+Fab+IgG), it being understood that said analogues of Fc fragments of human IgG are all fragments or subfragments of Fc and all synthetic or semisynthetic peptides containing peptide sequences present in the Fc fragment, as well as all derivatives of these fragments, subfragments, or peptides, provided that these fragments, subfragments, peptides, or derivatives fulfill the following conditions: they have properties that activate the differentiation of suppressive cells; they have properties that inhibit antibody-dependent cytotoxicity; they do not have properties that activate NK cells. |
priorityDate | 1983-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.